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STUDY QUESTION: Does septum resection improve reproductive outcomes in women with a septate uterus?
SUMMARY ANSWER: Hysteroscopic septum resection does not improve reproductive outcomes in women with a septate uterus.
WHAT IS KNOWN ALREADY: A septate uterus is a congenital uterine anomaly. Women with a septate uterus are at increased risk
of subfertility, pregnancy loss and preterm birth. Hysteroscopic resection of a septum may improve the chance of a live birth in affected
women, but this has never been evaluated in randomized clinical trials. We assessed whether septum resection improves reproductive
outcomes in women with a septate uterus, wanting to become pregnant.
STUDY DESIGN, SIZE, DURATION: We performed an international, multicentre, open-label, randomized controlled trial in 10 centres
in The Netherlands, UK, USA and Iran between October 2010 and September 2018.
PARTICIPANTS/MATERIALS, SETTING, METHODS: Women with a septate uterus and a history of subfertility, pregnancy loss
or preterm birth were randomly allocated to septum resection or expectant management. The primary outcome was conception leading
to live birth within 12 months after randomization, defined as the birth of a living foetus beyond 24 weeks of gestational age. We analysed
the data on an intention-to-treat basis and calculated relative risks with 95% CI.
MAIN RESULTS AND THE ROLE OF CHANCE: We randomly assigned 80 women with a septate uterus to septum resection
(n¼ 40) or expectant management (n¼ 40). We excluded one woman who underwent septum resection from the intention-to-treat
analysis, because she withdrew informed consent for the study shortly after randomization. Live birth occurred in 12 of 39 women
allocated to septum resection (31%) and in 14 of 40 women allocated to expectant management (35%) (relative risk (RR) 0.88 (95% CI
0.47 to 1.65)). There was one uterine perforation which occurred during surgery (1/39¼ 2.6%).
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LIMITATIONS, REASONS FOR CAUTION: Although this was a major international trial, the sample size was still limited and
recruitment took a long period. Since surgical techniques did not fundamentally change over time, we consider the latter of limited clinical
significance.
WIDER IMPLICATIONS OF THE FINDINGS: The trial generated high-level evidence in addition to evidence from a recently
published large cohort study. Both studies unequivocally do not reveal any improvements in reproductive outcomes, thereby questioning
any rationale behind surgery.
STUDY FUNDING/COMPETING INTEREST(S): There was no study funding. M.H.E. reports a patent on a surgical endoscopic
cutting device and process for the removal of tissue from a body cavity licensed to Medtronic, outside the scope of the submitted work.
H.A.v.V. reports personal fees from Medtronic, outside the submitted work. B.W.J.M. reports grants from NHMRC, personal fees from
ObsEva, personal fees from Merck Merck KGaA, personal fees from Guerbet, personal fees from iGenomix, outside the submitted
work. M.G. reports several research and educational grants from Guerbet, Merck and Ferring (location VUMC) outside the scope of the
submitted work. The remaining authors have nothing to declare.
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Introduction
The septate uterus is a congenital uterine anomaly. It is infrequently
detected, with an estimated prevalence of around 0.2–2.3% in
women of reproductive age (Saravelos et al., 2008; Chan et al.,
2011b). Women with a septate uterus are at increased risk for sub-
fertility, pregnancy loss and preterm birth (Chan et al., 2011a).
Hysteroscopic septum resection is currently standard practice to
restore normal uterine anatomy, with the aim of improving repro-
ductive outcomes.
At present, the American Society of Reproductive Medicine (ASRM)
guideline for management of the septate uterus recommends hystero-
scopic resection (ASRM, 2016). In contrast, guidance on recurrent
pregnancy loss associated with a septate uterus from the European
Society of Human Reproduction and Embryology (ESHRE), the
National Institute for Health and Care Excellence (NICE) and the
Royal College of Obstetricians and Gynaecologists (RCOG) do not
support the use of the procedure, until adequate studies would have
demonstrated its effectiveness (RCOG, 2011; NICE, 2015; ESHRE,
2018).
Recently, a large cohort study including 257 women with a septate
uterus, showed that surgery did not improve chance of conception,
nor did it appear to prevent pregnancy loss or preterm birth. Surgical
complications occurred in seven women (4.6%) (Rikken et al., 2020).
To provide a higher level of evidence, we here performed a ran-
domized controlled trial comparing hysteroscopic septum resection
with expectant management in women with a septate uterus.
Materials and methods
Design
This study was designed as an international, multicentre, open-label,
randomized controlled trial carried out in centres with expertise
in hysteroscopic septum resection. These centres were three
tertiary-care and four secondary-care hospitals collaborating in the
Dutch Consortium for Women’s Health Research, and three tertiary-
care hospitals in the USA, UK and Iran, respectively.
Ethical approval
The TRUST (The Randomised Uterine Septum Trial) trial was
registered within the Netherlands Trial Register, number NTR1676.
The trial protocol and all subsequent amendments were approved
by the Medical Ethical Committee of the Academic Medical Centre
(IDS NL24082.018.08 MEC Academic Medical Centre, Amsterdam),
The Netherlands on 28 October 2008 (MEC 08/245), and by the
boards of directors of all participating hospitals.
All adverse and serious adverse events suspected of having a causal
relationship to surgery were recorded. A serious adverse event was
defined as death or illness necessitating intensive care unit (ICU) treat-
ment. All serious adverse events had to be reported to the ethics
committee of the Academic Medical Centre, Amsterdam. The study
protocol has been published previously (Rikken et al., 2018).
Eligible women were provided with trial information verbally and in
writing by consultant gynaecologists or dedicated research employees
at the outpatient clinics. All women provided written informed con-
sent. Women could withdraw from the trial at any time.
Study population
Women of reproductive age with a septate uterus, wanting to become
pregnant and with a history of subfertility, pregnancy loss or preterm
birth were eligible. Women with a contraindication to surgery were
not eligible. Initially, after ethical study approval only women with re-
current pregnancy loss were included. During the course of the trial,
the eligibility criteria were extended to include women with a history
of subfertility (2011), one pregnancy loss or preterm birth (2015). This
broadening of inclusions was based on a systematic review published
in 2011 that showed that women with a septate uterus had reduced
clinical pregnancy rates and increased rates of pregnancy loss and






























































































..preterm birth when compared with women with normal uteri
(Chan et al., 2011a,b). A septate uterus was diagnosed by the treating
consultant according to the leading classification systems at that time
of recruitment (AFS, 1988; Grimbizis et al., 2013; ASRM, 2016). The
presence of a uterine septum had to be ascertained by hysterosalpin-
gography, 3-dimensional pelvic ultrasound, MRI, saline or gel infusion
sonohysterography or hysteroscopy combined with laparoscopy
(Faivre et al., 2012; Ludwin et al., 2013; Siam and Soliman, 2014;
Graupera et al., 2015).
Definitions
The following list of definitions was used. Subfertility: the inability to
conceive for a minimal period of 12 months of trying to conceive
(Zegers-Hochschild et al., 2017); Pregnancy loss: the spontaneous
demise of a pregnancy before 24 weeks of gestation, including non-
visualized or biochemical pregnancies, confirmed by either serum or
urine b-HCG; Recurrent pregnancy loss: two or more, not necessarily
consecutive, pregnancy losses (ESHRE, 2018); Preterm birth: birth be-
fore a gestational age of 37 complete weeks (Blencowe et al., 2013);
Clinical pregnancy: the presence of a foetal heartbeat at or beyond
6 weeks of pregnancy; Ongoing pregnancy: a viable intrauterine
pregnancy of at least 12 weeks duration, confirmed on an ultrasound
scan (Braakhekke et al., 2014).
Randomization and blinding
Women were randomly allocated (1:1) to hysteroscopic septum
resection or expectant management, by use of a central password
protected internet-based randomization programme. The randomiza-
tion list behind the programme was prepared by an independent
statistician with a variable block size with randomly selected block sizes
that varied between two, four and six. There was no stratification.
Neither the recruiters nor the trial project group could access the ran-
domization sequence. Because of the nature of the interventions,
blinding women or doctors was impossible.
Procedures
Women allocated to hysteroscopic septum resection had their surgical
procedure performed under general or loco-regional anaesthesia. The
choice of instrumentation was left to the participating surgeon, which
could include monopolar or bipolar resectoscopes with needle and/or
loop electrosurgical electrodes, bipolar vaporization electrodes
(VersapointVR ) or conventional mechanical scissors. To monitor the
depth of the myometrial resection and to prevent uterine perforation
during surgery, laparoscopic or ultrasound monitoring was advised
(Zhang et al., 2015). To assess the results of the septum resection, a
diagnostic control hysteroscopy 6–8 weeks postoperatively was per-
formed in an outpatient setting.
Women allocated to expectant management did not receive any
specific intervention and were advised to continue trying to conceive
naturally or with assisted reproductive technologies in case of subfertil-
ity. In women with recurrent pregnancy loss and co-existing antiphos-
pholipid syndrome, low dose aspirin or low molecular weight heparin
were allowed. Women could opt for hysteroscopic septum resection
if the first pregnancy after randomization resulted in a pregnancy loss
or if pregnancy did not occur after 1 year of follow-up.
Outcomes
The primary outcome measure was conception leading to live birth
within 12 months after randomization. Live birth was defined as the
birth of a living foetus beyond 24 weeks of gestational age. Secondary
outcomes included clinical pregnancy, pregnancy loss, ongoing preg-
nancy and preterm birth, with conception leading to these outcomes
within 12 months after randomization. In women with an ongoing
pregnancy, pregnancy outcomes such as multiple pregnancy, ectopic
pregnancy, placental abruption, uterine rupture and mode of delivery
were assessed. Data on specific complications during and following
hysteroscopic septum resection, like uterine perforation, fluid overload
and endometritis, were collected. We followed women for at least
1 year, and followed those who conceived within that period for the
course of that pregnancy. If women had a pregnancy loss within
1 year, we followed them until the next conception leading to live
birth if within 12 months after randomization, or otherwise until
12 months after randomization.
Sample size
For the sample size calculation, we estimated live birth rate to be 35%
in women with a septate uterus without surgery and we expected an
increase to 70% with surgery, based on retrospective studies (Homer
et al., 2000; Chan et al., 2011a). Using a two-sided test, an alpha-error
of 5% and a beta-error of 20%, 62 women were needed to demon-
strate this difference. Anticipating lost-to-follow-up and protocol viola-
tions, an additional 10% was needed. Thus, a minimum of 68 women
needed to be randomized. Because of the small sample size, we did
not plan an interim analysis.
Statistical analysis
We analysed the data on intention-to-treat basis. We calculated rela-
tive risks and 95% CIs for all pregnancy outcomes. To account for
time to conception leading to live birth, we constructed Kaplan–Meier
curves using the log-rank test to compare the treatment arms and cal-
culated the corresponding hazard rates with 95% CI. Additionally, we
performed a per-protocol analysis limited to women who were
treated according to their allocated study arm, regardless of first having
a pregnancy loss or not having become pregnant. We used SPSSVR
(IBM 2019, USA) software for all statistical analyses (version 25).
Results
Between 20 October 2010 and 3 September 2018, 80 women
were randomly assigned and allocated to septum resection (n¼ 40) or
expectant management (n¼ 40) (Fig. 1).
Baseline characteristics were similar between the two treatment
arms (Table I). Surgical details of women allocated to septum resection
are shown in Table II. One uterine perforation occurred immediately
after introduction of the hysteroscope, after which the surgeon
stopped the procedure without any further interventions needed. The









































septum was removed 4 weeks later without further complications.
Serious adverse events (death or illness necessitating ICU treatment)
were not reported. Seven women did not have monitoring via laparos-
copy or ultrasound during surgery, which we documented as a proto-
col deviation. There were 27 women (69%) who had a control
hysteroscopy at 6 weeks follow-up. Two women had a residual sep-
tum, including the woman with the uterine perforation. Both women
underwent a second procedure.
Reproductive outcomes
Reproductive outcomes are summarized in Table III. In the
intention-to-treat analysis, 12 of 39 women who were allocated to
septum resection (31%) had a live birth, compared to 14 of
40 women who were allocated to expectant management (35%);
this corresponds to a RR 0.88 (95% CI 0.47–1.7) and an absolute
risk difference of minus 4.2% (95% CI 24.9% to 16.5%). There
was also no evidence of a difference in clinical pregnancy, ongoing
pregnancy, pregnancy loss or preterm birth rates. The mean time to
conception leading to live birth was 9.8 months (95% CI 8.6 to 11)
following randomization for septum resection and 9.2 months
(95% CI 7.8 to 11) after randomization for expectant management
(log rank: P¼ 0.64). The corresponding hazard ratio (HR) was
0.83 (95% CI 0.39 to 1.9) (Fig. 2).
In women with an ongoing pregnancy, breech presentation at the
time of delivery occurred in two women were allocated to septum re-
section and in six women who were allocated to expectant manage-
ment (Table IV). Of 13 women who allocated to septum resection,
9 (69%) had a caesarean section while 5 of 14 women who allocated
to expectant management (36%) had a caesarean section (RR 1.9
(95% CI 0.88 to 5.0)). The reasons for a caesarean section in women
who were allocated to septum resection were elective reasons
(n¼ 3), non-progressive labour (n¼ 1), foetal distress (n¼ 1), placenta
praevia (n¼ 1) or unknown (n¼ 4), and the reasons in women who
were allocated to expectant management were breech presentation
(n¼ 3) or foetal distress (n¼ 2). Two women in the septum resection
arm had twin pregnancies (15%) versus none in the expectant manage-
ment arm. There were no cases of ectopic pregnancy, uterine rupture,
placental abruption, postpartum haemorrhage or intra-uterine foetal
death.
80 women randomly assigned 
40 allocated to expectant management 40 allocated to septum resection 
1 withdrew consent* 
39 analysed by intention-to-treat 40 analysed by intention-to-treat 
2 had expectant management** 
1 lost to follow up 
5 had septum resection*** 
2 lost to follow up 
36 analysed per-protocol 33 analysed per-protocol 
Figure 1. Trial profile. *One woman withdrew informed consent immediately after being randomized as she did not prefer a septum resection.
**Two women appeared to have no septate uterus at time of surgery and hence septum resection was cancelled. ***One woman had a septum
resection after 1 month, three women after 4 months and one woman after 9 months of follow-up.



















In line with the intention-to-treat analysis, the per-protocol analysis
showed no evidence of a difference in live birth, ongoing pregnancy,
clinical pregnancy, pregnancy loss or preterm birth, RR 0.92 (95% CI
0.55 to 1.5), RR 0.99 (95% CI 0.53 to 1.9), RR 1.1 (95% CI 0.74 to
1.7), RR 1.83 (95% CI 0.70 to 4.8) and RR 1.2 (95% CI 0.34 to 3.9),
for septum resection versus expectant management respectively)
(Table V).
Discussion
In this international, multicentre, open-label, randomized controlled
trial in women with a septate uterus, septum resection did not im-
prove live birth rates compared with expectant management. There
was also no evidence of a difference in other reproductive outcomes,
like ongoing pregnancy, pregnancy loss and preterm birth rates. One
complication of treatment, a perforation of the uterus, was sustained
during septum resection.
Our study has a number of strengths. We performed a pragmatic
study, in which we included women who had been diagnosed by their
treating gynaecologist in 10 centres in four countries worldwide, based
on the leading classification at that time. This reflects daily practices
and ensures a high generalizability of the study results. Whilst an
.......................................................................................................







Age (years)* 31.0 (29–32) 31.7 (30–33)
Parity
0 31 (80) 32 (80)
1 6 (15) 7 (18)
>1 2 (5) 1 (2)
BMI (kg/m2)* 25 (24–27) 25 (23–26)
Smoker
Yes 3 (8) 5 (13)
No 36 (92) 35 (87)
Inclusion criteria**
Pregnancy loss 23 (59) 27 (67)
Subfertility 15 (39) 13 (33)
Preterm birth 2 (5) 4 (10)
Diagnosis
Partial septum 35 (92) 36 (90)
Complete septum 3 (8) 4 (10)
Unknown 1
Diagnostic procedure***
SIS/GIS 4 (10) 4 (10)
3D ultrasound 11 (28) 15 (38)
MRI 6 (15) 7 (18)
Hysteroscopy þ laparoscopy 21 (54) 17 (43)
HSG 9 (23) 3 (7.5)
Data are in mean (standard deviation) or n (%).
*BMI, body mass index; GIS, gel infusion sonohysterography; HSG, hysterosalpingog-
raphy; MRI, magnetic resonance imaging; SIS, saline infusion sonohysterography.
**Women could have more than one inclusion criterium.
***Combinations of diagnostic procedures could have been used.
......................................................................................................






Resectoscope (needle- or loop electrode) 25 (64)
Vaporization electrode (VersapointVR ) 7 (18)
Mechanical—scissors 5 (13)











Repeat procedure (incomplete resection)
Yes 2 (5.1)
Data are in n (%).
*Successful was defined as removal of the septum without complications as assessed
at the end of the procedure.
**Hysteroscopy at 6 weeks of follow-up to assess the anatomy of the uterus.
......................................................................................................











Live birth 12 (31%) 14 (35%) 0.88 (0.47–1.7)
Secondary outcomes
Ongoing pregnancy* 13 (33%) 14 (35%) 0.95 (0.52–1.8)
Clinical pregnancy 22 (56%) 19 (48%) 1.2 (0.77–1.2)
Pregnancy loss** 11 (28%) 5 (13%) 2.3 (0.86–5.9)
Preterm birth 5 (13%) 4 (10%) 1.3 (0.37–4.4)
Data are in n (%).
RR, relative risk.
*One woman who underwent septum resection had an ongoing pregnancy that
ended in a late pregnancy loss at 17 weeks.
**One woman had a biochemical pregnancy that ended in a pregnancy loss at
5 weeks.

































































































accepted classification of uterine anomalies remains elusive
(Grimbizis et al., 2013; ASRM, 2016; Ludwin et al., 2018), it seems
unlikely that subtle changes in the definition of a uterine septum,
would impact substantially upon our findings. In addition, there was
a high compliance, i.e. only a few women were lost to follow-up
(4 women, 5%).
A limitation of our study is that with our sample size of 68 women,
we were able to detect an improvement in live birth from 35% to
70% with surgery, which we expected based on the existing literature
at the start of the study (Homer et al., 2000). To detect a smaller im-
provement of 10% in live births, for example from 35% to 45%, new
studies would need to recruit at least 752 women. Any effort to con-
firm or refute the results of this trial would thus need a worldwide,
dedicated and adequately resourced collaboration. Such an enterprise
is unlikely to be feasible, especially if one considers that the only other
randomized controlled trial comparing septum resection with expec-
tant management carried out in the UK was forced to stop because of
poor recruitment; six patients in a recruitment period of 3 years (pilot
randomized controlled trial of hysteroscopic septum resection,
ISRCTN28960271).
Our findings are in line with our recently published international
multicentre cohort study of 257 women with a septate uterus, which
showed no differences in live birth rates between women who under-
went septum resection and women following expectant management,
adjusted for possible confounders (53% vs 72%, respectively, HR 0.71,
95% CI 0.49 to 1.02) (Rikken et al., 2020).
Our study was not powered to evaluate any differential effect of
septum resection in women with pregnancy loss compared with
those presenting with subfertility, or according to the number of
pregnancy losses, nor was it powered to evaluate any possible dif-
ferential effect of the size of the uterine septum. Complete septa
are less common than incomplete septa and represented under
10% of our trial population. Of the seven women with a complete
septate uterus, live birth occurred in two of three women (66.7%)
who underwent septum resection, and 3 of 4 women (75%) who
had expectant management.
The findings of this randomized controlled trial show that hyster-
oscopic septum resection does not improve live birth rates or
other reproductive outcomes in women with a septate uterus. The
surgical procedure, by definition, has the propensity for harm, with
one peri-operative uterine perforation occurring in a woman un-
dergoing septum resection in this trial. Thus, in light of the lack of
any evidence of effectiveness and the potential for harm, we
recommend against septum resection as a routine procedure in
clinical practice. Women with a septate uterus need to be informed
about the data of this study. After counselling, according to the
principles of shared decision-making, an informed decision can then
be made.
Data availability
Request for data collected for the study can be made to the co-
corresponding authors and will be considered on an individual basis.
Additional, study-related documents are immediately available and can
be requested from the co-corresponding authors.
Figure 2. Kaplan–Meier analysis of cumulative live birth
rate in women who underwent septum resection and
women who had expectant management.
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Cephalic 11 (85%) 7 (54%) 1.6 (0.87–2.8)
Breech 2 (15%) 6 (46%)
Unknown 0 1
Mode of delivery
Caesarean section 9 (69%) 5 (36%) 1.9 (0.88–5.0)
Spontaneous 4 (31%) 9 (64%)
Data are in n (%).
RR, relative risk.
......................................................................................................










Live birth 12 (33%) 12 (36%) 0.92 (0.55–1.5)
Secondary outcomes
Ongoing pregnancy* 13 (36%) 12 (36%) 0.99 (0.53–1.9)
Clinical pregnancy 21 (58%) 17 (52%) 1.1 (0.74–1.7)
Pregnancy loss 10 (28%) 5 (15%) 1.8 (0.70–4.8)
Preterm birth 5 (14%) 4 (12%) 1.2 (0.34–3.9)
Data are in n (%).
RR, relative risk.
*One woman who underwent septum resection had an ongoing pregnancy that
ended in a late pregnancy loss at 17 weeks.
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